Randomized Trial on Effectiveness of ACTs in Ghana

Sponsor

Bernhard Nocht Institute for Tropical Medicine (Other)

Overall Status

Terminated

CT.gov ID

NCT00374205

Collaborator

Presbyterian Health Service (PHS) (Other), Kumasi Centre for Collaborative Research (KCCR) (Other), School of Medical Sciences Kumasi (SMS/KNUST) (Other)

245

Enrollment

Location

Arms

Duration (Months)

18.9

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to compare the effectiveness and safety of two Artemisinin Combination Therapies (ACTs) for the treatment of children with uncomplicated Plasmodium falciparum malaria

Condition or Disease	Intervention/Treatment	Phase
Malaria, Falciparum	Drug: Artesunate plus Amodiaquine Drug: Artemether-Lumefantrine	Phase 4

Detailed Description

Childhood mortality related to Plasmodium falciparum malaria is on the rise with more than 1 million deaths per year in Sub-Saharan Africa. In the context of growing drug-resistance to antimalarials health officials are calling for rapid replacement of failing drugs by combining antimalarial drugs. Artemisinin Combination Antimalarial Therapies (ACTs) are in the focus of malaria control programmes and are recommended for first-line treatment in African countries. ACTs have been reported to be highly effective as artemisinin derivatives cause a rapid and substantial decrease in the parasite load when used for treating patients with malaria and resistance to artemisinin is still lacking. However, the short half-lives of artemisinins result in frequent recrudescent infections when used alone and therefore, much interest lays on the choice of the combination partner drug. ACTs also have been proposed as a means of reducing transmission by the reduction of gametocytes and of delaying the spread of drug resistance and prolonging the therapeutic life span of. Nevertheless, drug resistance of parasites to the respective partner drug is a matter of concern. Artesunate-amodiaquine (AQ) and artemether-lumefantrine (AL) are two registered fixed-dose artemisinin combination chemotherapies used in Africa which are GMP-manufactured at industrial scale. There is still limited data from randomised, controlled trials to support the general effectiveness of these two ACTs in Africa, including Ghana. More data is needed to compare these two therapies to make evidence-based first-line treatment decisions. Importantly, it is difficult to predict how combination therapy may affect the spread of drug resistance and monitoring drug resistance markers should be embedded in these trials to guide drug policy decision.

The aim of this open-labelled, randomised drug trial is to compare the effectiveness and safety of artesunate-amodiaquine (Arsucam®) against artemether plus lumefantrine (Coartem®) for the treatment of children under five years of age with uncomplicated Plasmodium falciparum malaria.

Study Design

Study Type:

Interventional

Actual Enrollment :

245 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Comparative Assessment of the Effectiveness of Artemether Plus Lumefantrine Versus Artesunate Plus Amodiaquine for the Treatment of Children With Uncomplicated Plasmodium Falciparum Malaria

Study Start Date :

Sep 1, 2006

Actual Study Completion Date :

Oct 1, 2007

Arms and Interventions

Arm	Intervention/Treatment
Experimental: AL Artemether plus Lumefantrine 6 dose 3 days treatment	Drug: Artemether-Lumefantrine Artemether 20 mg/Lumefantrine 120mg fixe-dose-combination tablets: 3 days twice daily weight-adjusted dosing according to manufacturer Other Names: Coartem®
Active Comparator: ASAQ Artesunate plus Amodiaquine	Drug: Artesunate plus Amodiaquine Artesunate 50 mg and Amodiaquine 153 mg co-blister tablets: 3 days once daily weight-adjusted dosing according to manufacturer Other Names: Arsucam®

Arm

Intervention/Treatment

Experimental: AL

Artemether plus Lumefantrine 6 dose 3 days treatment

Drug: Artemether-Lumefantrine

Artemether 20 mg/Lumefantrine 120mg fixe-dose-combination tablets: 3 days twice daily weight-adjusted dosing according to manufacturer

Other Names:

Coartem®

Active Comparator: ASAQ

Artesunate plus Amodiaquine

Drug: Artesunate plus Amodiaquine

Artesunate 50 mg and Amodiaquine 153 mg co-blister tablets: 3 days once daily weight-adjusted dosing according to manufacturer

Other Names:

Arsucam®

Outcome Measures

Primary Outcome Measures

Clinical and PCR-controlled parasitological cure rate at day 28 [28 days]

Secondary Outcome Measures

Clinical and PCR-controlled parasitological cure rate at day 14 [14 days]
Effect on anaemia [28 days]
Molecular Drug Resistance Markers [28 days]
Recrudescence and Reinfection [28 days]
Effects on Gametocytemia [28 days]
Acceptance of Therapies [7 days]
Incidences of malaria episodes over a follow-up period of 1 year [12 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:

6 Months to 59 Months

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Male and female outpatients aged 6 months to 59 months
Absence of severe malnutrition
A slide-confirmed P. falciparum asexual parasitaemia between 2,000/µl and 200,000/µl
A measured axillary temperature ≥ 37.5 °C or rectal/tympanic temperature ≥ 38.0 °C
Absence of general danger signs (unable to drink; repeated vomiting; recent history of convulsions; lethargic or unconscious state; unable to stand up or to sit)
Ability to tolerate oral therapy
Permanent residence in study area
Informed consent by the legal representative of the subject, if possible, the parents

Exclusion Criteria:

Adequate anti-malarial treatment within the previous 7 days
Antibiotic treatment for a current infection
Previous participation in a clinical trial
Haemoglobin < 5 g/dl
Leucocyte count: > 15000/µl
Mixed plasmodial infection
Severe malaria as defined by WHO recommendations
Any other severe underlying disease (cardiac, renal, hepatic diseases, malnutrition, known HIV infection) or concomitant disease masking assessment of response
History of allergy or intolerance against trial medication